guidebook. - Fanconi Anemia Research Fund

More documents

Recommendations

Info

Index 385 nausea, 79-82, 212-213, 218, 313 neurological, neurocognitive issues, 79, 84, 214, 225, 231; neuropsychology evaluation, 227, 232 neutropenia, neutropenic, 49, 60, 68, 70-71, 73-74, 84, 175, 215, 359 neutrophil count, absolute neutrophil count, 57, 60-61, 73, 184, 187, 198, 200, 331 North American Survey (NAS), 264 novel treatment options, 236-249 nutrition, 76, 139-140; bone age, affected by, 138; diet, see diet; HSCT, assessment of nutrition prior or during, 91, 158, 202; marrow failure, affected by, 53; megaloblastic anemias, as caused by, 49; nutrition as therapy, 93-94; overweight, see obesity, overweight; post-HSCT nutritional issues, 225, 228; supplemental nutrition, 82-85; underweight, see underweight obesity, overweight, 87-88; 139-140, 149-150; central obesity, 228; diet, see diet; eating disorder, 87; glucocorticoids and anticonvulsant therapy, effect on, 158; impact of non-alcoholic steatohepatitis or liver disease on, 87; metabolic syndrome, see metabolic syndrome; nutrition, see nutrition; over-the-counter weight loss preparations, 88; sleep disorder or snoring related to, 87 obliterative bronchiolitis, 213 odynophagia, 253, 255, 359 oral cavity, 250, 252, 255, 258-259, 261-262, see also head and neck squamous cell carcinoma oral dryness, 213; pain, 213, 253 oropharynx, 250, 252, 255, 259, 267, 350, 360, see also head and neck squamous cell carcinoma osteopenia, osteoporosis, 124, 129-130, 134, 154-156, 159, 227; bone mineral density, 138-140, 152, 154-157, 159, 337; bone therapy, 155-156; dual energy absorptiometry (DXA) scan, 130, 138, 155-156, 227, 232, 342; T-score, 155, 367; Z-score, 138, 155, 369 ova and parasites, 80 ovarian, 127-128, 153; atresia, 121; failure, 39, 127, 157; function, effect of anticonvulsant therapy on, 158; tissue cryopreservation, 128 oxidative stress, 93, 147, 243-244, 360 pain, abdominal, 78-80, 91, 213; breast, 283; chronic, 202; colon interposition, pain from, 78; eye pain, with GvHD, 213; gastroesophageal reflux or tracheoesophageal fistula, pain from, 78; hepatomegaly, pain with, 88; intestinal stricture, pain with,
386 <strong>Fanconi</strong> <strong>Anemia</strong>: Guidelines for Diagnosis and Management 92; oral, with GvHD, 213; oral, throat or neck, 253; parotid gland, 212; sedation and analgesia for invasive procedures, 74, 313 pancreas, 68, 140; pancreatic beta cell dysfunction, 159; pancreatic insufficiency, 92 pancytopenia, 213, 360 penis, 35, 58, 357 peptic disorders, see gastrointestinal issues peritonitis, 84, 361 phalanx, 105-107, 114, 361 physicians, response to psychosocial issues, 305-306; role in grieving process, 310-316 pituitary, 68, 138-140, 142-143, 150-151, 158-159, 362 platelets, 53, 57, 72-73, 84, 94, 124, 198, 362 pneumonia, 78 polydactyly, pre-axial, 106 polypharmacy, 76, 363 potassium, 214 pregnancy, 128-129, 268; uterine bleeding, 123; amniocentesis, 286-287, 333; androgen use during, 123; cryopreservation of embryos, sperm, and ovarian tissue, 128, 154; discuss childbearing options pre-transplant, 127; complications, 129, 225; preimplantation genetic diagnosis, see preimplantation genetic diagnosis; pre-natal testing, 33-34, 37, 62, 278-279, 363; reproductive options and family planning, 33, 127-128, 275-276, 283, 285 preimplantation genetic diagnosis (PGD), 62, 194, 219, 285-287, 295-296 proband, 45, 363 prolactin, 158 pseudomembrane formation, 213 psychosocial issues, 225, 271-272, 291-306, 363; high-risk behaviors, 298, 302; recommendations for the physician, 305-306 puberty, 151-153, 159, 363; breast buds, 122, 151; delay, 134, 138-139, 151-153, 156, 232, 363; early onset, 138, 151; relation of to age at transplant, 127; treatment benefits of for bone mineralization, 156 pulmonary, complications, post-transplant, 186, 194; function, 186, 233 quality of life, 66, 156, 160, 217, 224, 231, 233, 312, 314 radial ray, 43, 364; abnormalities, 107-117, 364; carpectomy, 113, 338; centralization, 112-115; classification of radial deficiency,
Page 1 and 2:
Fanconi Anemia: Guidelines for Diag
Page 3 and 4:
We are deeply grateful to the follo
Page 5 and 6:
iv Fanconi Anemia: Guidelines for D
Page 7 and 8:
vi Fanconi Anemia: Guidelines for D
Page 9 and 10:
8 Fanconi Anemia: Guidelines for Di
Page 11 and 12:
10 Fanconi Anemia: Guidelines for D
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Chapter 4 Gastrointestinal, Hepatic
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
100 Fanconi Anemia: Guidelines for
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Chapter 7 Endocrine Disorders in Fa
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Chapter 9 Matched Sibling Donor Hem
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Chapter 12 Novel Treatment Options
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Chapter 13 Head and Neck Squamous C
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Chapter 14 The Adult Fanconi Anemia
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336: 334 Fanconi Anemia: Guidelines for
Page 385: 384 Fanconi Anemia: Guidelines for
show all

guidebook. - Fanconi Anemia Research Fund

Create successful ePaper yourself

Delete template?

Save as template?